Cargando…
C9orf72-G(4)C(2) Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis
Pathogenic C9orf72-G(4)C(2) repeat expansions are associated with ALS/FTD, but not with Parkinson’s disease (PD); yet the possible link between intermediate repeat lengths and PD remains inconclusive. We aim to study the potential involvement of these repeats in PD. The number of C9orf72-repeats wer...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391122/ https://www.ncbi.nlm.nih.gov/pubmed/34440384 http://dx.doi.org/10.3390/genes12081210 |
_version_ | 1783743196953575424 |
---|---|
author | Kobo, Hila Goldstein, Orly Gana-Weisz, Mali Bar-Shira, Anat Gurevich, Tanya Thaler, Avner Mirelman, Anat Giladi, Nir Orr-Urtreger, Avi |
author_facet | Kobo, Hila Goldstein, Orly Gana-Weisz, Mali Bar-Shira, Anat Gurevich, Tanya Thaler, Avner Mirelman, Anat Giladi, Nir Orr-Urtreger, Avi |
author_sort | Kobo, Hila |
collection | PubMed |
description | Pathogenic C9orf72-G(4)C(2) repeat expansions are associated with ALS/FTD, but not with Parkinson’s disease (PD); yet the possible link between intermediate repeat lengths and PD remains inconclusive. We aim to study the potential involvement of these repeats in PD. The number of C9orf72-repeats were determined by flanking and repeat-primed PCR assays, and the risk-haplotype was determined by SNP-array. Their association with PD was assessed in a stratified manner: in PD-patients-carriers of mutations in LRRK2, GBA, or SMPD1 genes (n = 388), and in PD-non-carriers (NC, n = 718). Allelic distribution was significantly different only in PD-NC compared to 600 controls when looking both at the allele with higher repeat’s size (p = 0.034) and at the combined number of repeats from both alleles (p = 0.023). Intermediate repeats (20–60 repeats) were associated with PD in PD-NC patients (p = 0.041; OR = 3.684 (CI 1.05–13.0)) but not in PD-carriers (p = 0.684). The C9orf72 risk-haplotype, determined in a subgroup of 588 PDs and 126 controls, was observed in higher frequency in PD-NC (dominant model, OR = 1.71, CI 1.04–2.81, p = 0.0356). All 19 alleles within the risk-haplotype were associated with higher C9orf72 RNA levels according to the GTEx database. Based on our data, we suggest a model in which intermediate repeats are a risk factor for PD in non-carriers, driven not only by the number of repeats but also by the variants’ genotypes within the risk-haplotype. Further studies are needed to elucidate this possible role of C9orf72 in PD pathogenesis. |
format | Online Article Text |
id | pubmed-8391122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83911222021-08-28 C9orf72-G(4)C(2) Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis Kobo, Hila Goldstein, Orly Gana-Weisz, Mali Bar-Shira, Anat Gurevich, Tanya Thaler, Avner Mirelman, Anat Giladi, Nir Orr-Urtreger, Avi Genes (Basel) Article Pathogenic C9orf72-G(4)C(2) repeat expansions are associated with ALS/FTD, but not with Parkinson’s disease (PD); yet the possible link between intermediate repeat lengths and PD remains inconclusive. We aim to study the potential involvement of these repeats in PD. The number of C9orf72-repeats were determined by flanking and repeat-primed PCR assays, and the risk-haplotype was determined by SNP-array. Their association with PD was assessed in a stratified manner: in PD-patients-carriers of mutations in LRRK2, GBA, or SMPD1 genes (n = 388), and in PD-non-carriers (NC, n = 718). Allelic distribution was significantly different only in PD-NC compared to 600 controls when looking both at the allele with higher repeat’s size (p = 0.034) and at the combined number of repeats from both alleles (p = 0.023). Intermediate repeats (20–60 repeats) were associated with PD in PD-NC patients (p = 0.041; OR = 3.684 (CI 1.05–13.0)) but not in PD-carriers (p = 0.684). The C9orf72 risk-haplotype, determined in a subgroup of 588 PDs and 126 controls, was observed in higher frequency in PD-NC (dominant model, OR = 1.71, CI 1.04–2.81, p = 0.0356). All 19 alleles within the risk-haplotype were associated with higher C9orf72 RNA levels according to the GTEx database. Based on our data, we suggest a model in which intermediate repeats are a risk factor for PD in non-carriers, driven not only by the number of repeats but also by the variants’ genotypes within the risk-haplotype. Further studies are needed to elucidate this possible role of C9orf72 in PD pathogenesis. MDPI 2021-08-05 /pmc/articles/PMC8391122/ /pubmed/34440384 http://dx.doi.org/10.3390/genes12081210 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kobo, Hila Goldstein, Orly Gana-Weisz, Mali Bar-Shira, Anat Gurevich, Tanya Thaler, Avner Mirelman, Anat Giladi, Nir Orr-Urtreger, Avi C9orf72-G(4)C(2) Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis |
title | C9orf72-G(4)C(2) Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis |
title_full | C9orf72-G(4)C(2) Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis |
title_fullStr | C9orf72-G(4)C(2) Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis |
title_full_unstemmed | C9orf72-G(4)C(2) Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis |
title_short | C9orf72-G(4)C(2) Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis |
title_sort | c9orf72-g(4)c(2) intermediate repeats and parkinson’s disease; a data-driven hypothesis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391122/ https://www.ncbi.nlm.nih.gov/pubmed/34440384 http://dx.doi.org/10.3390/genes12081210 |
work_keys_str_mv | AT kobohila c9orf72g4c2intermediaterepeatsandparkinsonsdiseaseadatadrivenhypothesis AT goldsteinorly c9orf72g4c2intermediaterepeatsandparkinsonsdiseaseadatadrivenhypothesis AT ganaweiszmali c9orf72g4c2intermediaterepeatsandparkinsonsdiseaseadatadrivenhypothesis AT barshiraanat c9orf72g4c2intermediaterepeatsandparkinsonsdiseaseadatadrivenhypothesis AT gurevichtanya c9orf72g4c2intermediaterepeatsandparkinsonsdiseaseadatadrivenhypothesis AT thaleravner c9orf72g4c2intermediaterepeatsandparkinsonsdiseaseadatadrivenhypothesis AT mirelmananat c9orf72g4c2intermediaterepeatsandparkinsonsdiseaseadatadrivenhypothesis AT giladinir c9orf72g4c2intermediaterepeatsandparkinsonsdiseaseadatadrivenhypothesis AT orrurtregeravi c9orf72g4c2intermediaterepeatsandparkinsonsdiseaseadatadrivenhypothesis |